Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Identification of Novel Combination Therapies Active in BCL2 Inhibitor-Resistant Patient-Derived AML Models

Courtney L Andersen, PhD, Amanda L Christie, MS, Alan Rosen, MS, Kim Maratea, DVM, PhD, Maureen Hattersley, Jon Travers, PhD, Justin Cidado, PhD, Sai Pulukuri, PhD, Jamal Saeh, PhD, Edwin Clark, PhD, Corinne Reimer, PhD, Jerome Mettetal, PhD

Blood (2019) 134 (Supplement_1): 1273.

https://doi.org/10.1182/blood-2019-129475

Published: 2019

Journal Articles

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas

Raphael Koch, Amanda L. Christie, Jennifer L. Crombie, Adam C. Palmer, Deborah Plana, Kay Shigemori, Sara N. Morrow, Alexandria Van Scoyk, Wenchao Wu, Elizabeth A. Brem, J. Paul Secrist, Lisa Drew, Alwin G. Schuller, Justin Cidado, Anthony Letai, David M. Weinstock

Blood (2019) 133 (6): 566–575.

https://doi.org/10.1182/blood-2018-07-865527

Published: 2019

Includes: Supplemental data

Journal Articles

Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma

Elena Battistello, Natalya Katanayeva, Elie Dheilly, Daniele Tavernari, Maria C. Donaldson, Luca Bonsignore, Margot Thome, Amanda L. Christie, Mark A. Murakami, Olivier Michielin, Giovanni Ciriello, Vincent Zoete, Elisa Oricchio

Blood (2018) 131 (21): 2345–2356.

https://doi.org/10.1182/blood-2017-10-809210

Published: 2018

Includes: Supplemental data

Journal Articles

In Vitro andpre-Clinical In Vivo evidence Support MDMX/MDM2 As Common Vulnerabilities across TP53 -Wild-Type T-Cell Lymphomas That Are Targetable with the α-Helical p53 Stapled Peptide Alrn-6924

Raphael Koch, MD, Amanda L Christie, BS, Noriaki Yoshida, MD PhD, Samuel Y. Ng, MDPhD, Kay Shigemori, Sara N Morrow, Alexandria Van Scoyk, Steven M. Horwitz, MD, Eric Jacobsen, MD, Solimar Santiago, Jian-Guo Ren, Vincent Guerlavais, PhD, D. Allan Annis, Manuel A. Aivado, MD PhD, David M. Weinstock, MD

Blood (2017) 130 (Supplement 1): 571.

https://doi.org/10.1182/blood.V130.Suppl_1.571.571

Published: 2017

Journal Articles

A Functional Approach to Precision Medicine Identifies Targeted Therapies for Acute Myeloid Leukemia

Shruti Bhatt, PhD, Vineeth Kumar Murali, Holly Zhu, Sophia Adamia, PhD, Amanda L Christie, BS, David M. Weinstock, MD, Jackie S Garcia, MD, Anthony Letai, MD PhD

Blood (2017) 130 (Supplement 1): 853.

https://doi.org/10.1182/blood.V130.Suppl_1.853.853

Published: 2017

Journal Articles

Circulating Micrornas (miRNA) As a Novel Liquid Biopsy and Therapeutic Platform in MYC and Non-MYC Diffuse Large B-Cell Lymphoma (DLBCL)

Afshin Beheshti, PhD, Charles Vanderburg, PhD, Ravi Dashnamoorthy, PhD, John Tyson McDonald, PhD, Amanda L Christie, BS, Kay Shigemori, Hallie Jester, Hong Zhang, PhD, David M. Weinstock, MD, Andrew M Evens, DO,MSc

Blood (2017) 130 (Supplement 1): 4005.

https://doi.org/10.1182/blood.V130.Suppl_1.4005.4005

Published: 2017

Journal Articles

Dynamic BH3 Profiling Reveals Novel Therapeutic Strategies for the Treatment of Double-Hit Lymphoma

Jennifer Crombie, MD, Chen Lossos, BS, Kristopher Sarosiek, PhD, Amanda L Christie, BS, Cameron Fraser, BS, Shruti Bhatt, PhD, Jing Deng, PhD, Matthew S. Davids, MD, David M. Weinstock, MD, Anthony Letai, MD PhD

Blood (2017) 130 (Supplement 1): 2764.

https://doi.org/10.1182/blood.V130.Suppl_1.2764.2764

Published: 2017

Journal Articles

Harnessing the Tumor Microenvironment for the Treatment of Double Hit Lymphoma

Chen Lossos, Yunpeng Liu, Amanda L. Christie, BS, Michael T. Hemann, PhD, David M Weinstock

Blood (2016) 128 (22): 47.

https://doi.org/10.1182/blood.V128.22.47.47

Published: 2016

Journal Articles

T-Cell Lymphoma Patient-Derived Xenografts and Newly Developed Cell Lines Recapitulate Aspects of Disease Biology and Represent Novel Tools for Preclinical Drug Development

Blood (2016) 128 (22): 3015.

https://doi.org/10.1182/blood.V128.22.3015.3015

Published: 2016

Journal Articles

Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia

Sara Buhrlage, PhD, Ellen Weisberg, MD, Nathan Schauer, Jing Yang, PhD, Ilaria Lamberto, PhD, Laura Doherty, Atsushi Nonami, MDPhD, Amanda L. Christie, BS, David M. Weinstock, MD, Richard M. Stone, MD, Nathanael Gray, PhD, James D Griffin, MD

Blood (2016) 128 (22): 524.

https://doi.org/10.1182/blood.V128.22.524.524

Published: 2016

Journal Articles

Notch-Regulated Enhancers in B-Cell Lymphoma Activate MYC and Potentiate B-Cell Receptor Signaling

Russell J.H. Ryan, MD, Jelena Petrovic, PhD, Dylan Rausch, BS, Caleb Lareau, BS, Winston Lee, MD PhD, Laura Donohue, BS, Amanda L. Christie, BS, Shawn Gillespie, BS, Michael J. Kluk, MD PhD, Valentina Nardi, MD, Robert B. Faryabi, PhD, Ephraim P. Hochberg, MD, David M. Weinstock, MD, Bradley E. Bernstein, MD PhD, Jon C. Aster, MD PhD, Warren S. Pear, MD PhD

Blood (2016) 128 (22): 457.

https://doi.org/10.1182/blood.V128.22.457.457

Published: 2016

Journal Articles

HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma

Caron Jacobson, Nadja Kopp, Jacob V. Layer, Robert A. Redd, Sebastian Tschuri, Sarah Haebe, Diederik van Bodegom, Liat Bird, Amanda L. Christie, Alexandra Christodoulou, Amy Saur, Trevor Tivey, Stefanie Zapf, Deepak Bararia, Ursula Zimber-Strobl, Scott J. Rodig, Oliver Weigert, David M. Weinstock

Blood (2016) 128 (21): 2517–2526.

https://doi.org/10.1182/blood-2016-04-711176

Published: 2016

Includes: Supplemental data

Journal Articles

Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease

Blood (2016) 127 (18): 2203–2213.

https://doi.org/10.1182/blood-2015-09-672352

Published: 2016

Includes: Supplemental data

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401 In Vivo

Amanda L Christie, B.S., Yvonne Li, PhD, Katsuhiro Togami, MD, Mahmoud Ghandi, PhD, Alexandra N. Christodoulou, M.S., Kevin Buczkowski, Fanny Angelot-Delettre, PhD, Sabeha Biichle, Janice Chen, PhD, Christopher L. Brooks, PhD, David M. Weinstock, MD, Francine Garnache-Ottou, PhD, Peter S Hammerman, MD PhD, Andrew A Lane, MD PhD

Blood (2015) 126 (23): 3797.

https://doi.org/10.1182/blood.V126.23.3797.3797

Published: 2015

Journal Articles

Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma

Mark A. Murakami, MD MA, Alexandra N. Christodoulou, M.S., Amanda L Christie, B.S., Tiffany DeSouza, B.S., Abner Louissaint, Jr., MD PhD, Una Vojinovic, B.S., Raphael Koch, MD, Loretta S. Li, MD, Scott P. Kallgren, PhD, Prakash Rao, PhD, Johannes Köster, PhD, Raga Vadhi, M.S., Eilene Duberow, B.S., Elizabeth A. Morgan, MD, Hongjun Wang, Samia S. Ahmed, Katharine L. Majewski, Marina Konopleva, MD PhD, Jerome Tamburini, MD, PhD, Alejandro Gutierrez, MD, Michelle Kelliher, PhD, Julia Etchin, PhD, Irmela Jeremias, MD, Andrew P. Weng, MD PhD, Andrew L Kung, MD PhD, Andrew A Lane, MD PhD, Francine Garnache-Ottou, PhD, Shai Izraeli, MD Prof, Eric Jacobsen, MD, Ilene Galinsky, ANP, Richard M. Stone, MD, Marian H. Harris, MD PhD, David M. Dorfman, MD PhD, Jon C Aster, MDPhD, Henry Long, PhD, Lewis B. Silverman, MD, David M Weinstock, MD

Blood (2015) 126 (23): 3252.

https://doi.org/10.1182/blood.V126.23.3252.3252

Published: 2015

Journal Articles

B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development

Blood (2015) 126 (23): 4001.

https://doi.org/10.1182/blood.V126.23.4001.4001

Published: 2015

Journal Articles

Diffuse Large B-Cell Lymphoma Patient-Derived Xenograft Models Capture Molecular and Biologic Heterogeneity and Inform Therapy

Blood (2015) 126 (23): 817.

https://doi.org/10.1182/blood.V126.23.817.817

Published: 2015

Journal Articles

The MDM2 Inhibitor NVP-CGM097 Is Highly Active in a Randomized Preclinical Trial of B-Cell Acute Lymphoblastic Leukemia Patient Derived Xenografts

Elizabeth C Townsend, PhD, Tiffany DeSouza, B.S., Mark A. Murakami, MD MA, Joan Montero, PhD, Kristen Stevenson, MS, Amanda L Christie, B.S., Alexandra N Christodolou, M.Sc., Una Vojinovic, B.S., Nadja Kopp, M.S., Patrizia Barzaghi-Rinaudo, Masato Murakami, MD, PhD, Anthony Letai, MD PhD, Sebastien Jeay, Jens Wuerthner, Ensar Halilovic, David M. Weinstock

Blood (2015) 126 (23): 797.

https://doi.org/10.1182/blood.V126.23.797.797

Published: 2015

Journal Articles

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach

Atsushi Nonami, Martin Sattler, Ellen Weisberg, Qingsong Liu, Jianming Zhang, Matthew P. Patricelli, Amanda L. Christie, Amy M. Saur, Nancy E. Kohl, Andrew L. Kung, Hojong Yoon, Taebo Sim, Nathanael S. Gray, James D. Griffin

Blood (2015) 125 (20): 3133–3143.

https://doi.org/10.1182/blood-2014-12-615906

Published: 2015

Includes: Supplemental data

Journal Articles

Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs)

Blood (2014) 124 (21): 3713.

https://doi.org/10.1182/blood.V124.21.3713.3713

Published: 2014

NARROW

Identification of Novel Combination Therapies Active in BCL2 Inhibitor-Resistant Patient-Derived AML Models

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas

Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma

In Vitro andpre-Clinical In Vivo evidence Support MDMX/MDM2 As Common Vulnerabilities across TP53 -Wild-Type T-Cell Lymphomas That Are Targetable with the α-Helical p53 Stapled Peptide Alrn-6924

A Functional Approach to Precision Medicine Identifies Targeted Therapies for Acute Myeloid Leukemia

Circulating Micrornas (miRNA) As a Novel Liquid Biopsy and Therapeutic Platform in MYC and Non-MYC Diffuse Large B-Cell Lymphoma (DLBCL)

Dynamic BH3 Profiling Reveals Novel Therapeutic Strategies for the Treatment of Double-Hit Lymphoma

Harnessing the Tumor Microenvironment for the Treatment of Double Hit Lymphoma

T-Cell Lymphoma Patient-Derived Xenografts and Newly Developed Cell Lines Recapitulate Aspects of Disease Biology and Represent Novel Tools for Preclinical Drug Development

Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia

Notch-Regulated Enhancers in B-Cell Lymphoma Activate MYC and Potentiate B-Cell Receptor Signaling

HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma

Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401 In Vivo

Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma

B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development

Diffuse Large B-Cell Lymphoma Patient-Derived Xenograft Models Capture Molecular and Biologic Heterogeneity and Inform Therapy

The MDM2 Inhibitor NVP-CGM097 Is Highly Active in a Randomized Preclinical Trial of B-Cell Acute Lymphoblastic Leukemia Patient Derived Xenografts

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach

Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only